如何确定VTE抗凝最佳疗程:基于证据的决策分析框架
本文提出一种决策分析框架,用于确定静脉血栓栓塞症(VTE)抗凝的最佳疗程,替代依赖医生直觉和指南小组判断的现行做法。该框架整合获益与危害的最佳证据,并系统纳入患者价值观与偏好,应用于3个临床场景:无诱因VTE、长途旅行相关VTE和肝硬化门静脉血栓。
要点
- 决策分析框架可透明整合证据与患者偏好,优化抗凝疗程决策。
- 该框架适用于无诱因VTE、长途旅行相关VTE及肝硬化门静脉血栓。
- 方法支持个体化、循证、以患者为中心的抗凝推荐。
核心结论
- 决策分析框架可透明整合最佳证据与患者价值观,支持个体化抗凝疗程推荐。
研究设计与样本
- 本文为方法学文章,介绍一种在临床实践中采用的决策分析框架,并应用于3个临床场景。
主要发现
- 该框架将医生和指南小组的直觉形式化,提供获益与危害证据的显式透明整合。
- 框架包含系统 eliciting 患者价值观与偏好的方法,以确定最佳抗凝疗程。
临床怎么用
- 临床可用于无诱因VTE、长途旅行相关VTE和肝硬化门静脉血栓的抗凝疗程决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
When advising patients on the optimal duration of anticoagulation for venous thromboembolism (VTE), current management often relies on the intuition of treating physicians and guideline panels, an approach that remains opaque to outside observers. We present a decision-analytical framework adopted in our practice. This approach formalizes the intuition of physicians and guideline panels, providing an explicit and transparent integration of the best available evidence on benefits and harms. It also incorporates a systematic method for eliciting patient values and preferences to determine the optimal duration of anticoagulation. To demonstrate the practical utility of the decision-analytical approach, we apply it to 3 clinical scenarios: unprovoked VTE, VTE related to long-haul travel, and portal vein thrombosis in cirrhosis. By transparently synthesizing evidence and patient values, this method supports individualized, evidence-based, patient-centered recommendations for the duration of anticoagulation, and it is applicable to solving similar clinical problems in hematology and medicine.
引用
- Djulbegovic B, Greenberg C. How to determine the optimal duration of anticoagulation for VTE: an evidence-based decision-analytical approach. Blood Adv. 2026. PMID: 41558032. doi:10.1182/bloodadvances.2025017976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。